• Molecular NameLinezolid
  • Synonymlinezolid
  • Weight337.351
  • Drugbank_IDDB00601
  • ACS_NO165800-03-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.99
  • pka1.8
  • LogD (pH=7, predicted)0.99
  • Solubility (experiment)3 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.86
  • LogSw (predicted, AB/LogsW2.0)0.72
  • Sw (mg/ml) (predicted, ACD/Labs)0.44
  • No.of HBond Donors1
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds4
  • TPSA71.11
  • StatusFDA approved
  • AdministrationIntravenous infusion, oral
  • PharmacologyA synthetic antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding31.0
  • Volume of distribution (VD)0.57~0.71 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (50–70%, CYP not involved)
  • Half life5.2 h
  • ExcretionNonrenal, renal, and fecal
  • Urinary Excretion35
  • Clerance2.1 ml/min/kg
  • ToxicityClinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A